Bacteria	Ceftazidime/cefepime	Ceftriaxone/cefotaxime	Fluoroquinolones*	Clindamycin	Aminoglycosides†	Ertapenem	Imipenem/meropenem	Pip-tazo/ticar-clav	Linezolid	Vancomycin	Tige-cycline
Staphylococcus aureus (MS)	+	++/+++	+++	++++	++	++++	++++	++++	++++	++++	++++
S aureus (MR)	–	–	–	+/++	+	–	++	–/+	++++	++++	++++
Staphylococcus epidermidis (MS)	+	++/+++	+++	+++	+	++	++++	++++	++++	++++	++++
S epidermidis (MR)	–	–	–	+	+	–	++	–/+	++++	++++	++++
Enterococcus faecalis (VS)	–	–	+	++	+	–	+++	++++	++++	++++	++++
E faecalis (VR)	–	–	–	–/+	+	–	+	+	++++	–	++++
Enterococcus faecium (VS)	–	–	+	–/+	+	–	+	+	++++		++++
E faecium (VR)	–	–	–	–/+	+	–	–	–	++++		–

^*Includes ciprofloxacin, levofloxacin and moxifloxacin;

^†Includes gentamicin, netilmicin, tobramycin and amikacin. – Poor activity; + Limited activity and/or resistance ≥15%; ++ Moderate to good activity and/or resistance 10% to 14%; +++ Very good activity and/or resistance 5% to 9%; ++++ Excellent activity and/or resistance <5%; MR Methicillin resistant; MS Methicillin sensitive; Pip-tazo Pipercillin-tazobactam; Ticar-clav Ticarcillin-clavulanate; VR Vancomycin resistant; VS Vancomycin sensitive. Data adapted from references 216,248–255